Ovuplant (Canada)This page contains information on Ovuplant for veterinary use.
The information provided typically includes the following:
- Ovuplant Indications
- Warnings and cautions for Ovuplant
- Direction and dosage information for Ovuplant
OvuplantThis treatment applies to the following species:
Implantable Sustained Release Gonadotropin Releasing Hormone (GnRH)
Analog (deslorelin) for Ovulation Induction in Mares
For Veterinary Use Only
OVUPLANT (deslorelin) is a synthetic GnRH analog in a biocompatible sustained release subcutaneous implant with the indication to induce ovulation in the estrous mare within 48 hours. OVUPLANT is formulated as a cylindrical implant in a preloaded syringe with an attached needle (implanter).
Each implant contains 2.1 mg deslorelin (as deslorelin acetate) in an inert matrix. The implant is white, cylindrical and approximately 2.3 mm in diameter and 3.6 mm in length.
The long duration of estrus in mares and the varying time from the onset of estrus to ovulation, typically results in the need for multiple breedings, or inseminations in order to achieve conception. OVUPLANT has been shown to induce ovulation within 48 hours after treatment in more than 86% of mares with a developing follicle greater than 30 mm in diameter. Deslorelin induces ovulation by increasing the levels of endogenous LH. Induction of ovulation decreases the duration of estrus and reduces the number of breedings required.
This product is intended to optimize breeding management through shortening the estrous period. By reducing the number of breedings to achieve conception, stallions may be more efficiently managed. When used to induce ovulation in mares being bred by artificial insemination of fresh cooled or frozen semen, the number of inseminations can be reduced. Abnormalities in neonatal viability and foal behavior related to the use of deslorelin have not been observed in foals born to treated mares.
OVUPLANT is indicated for inducing ovulation within 48 hours in estrous mares with an ovarian follicle greater than 30 mm in diameter. Follicular size should be determined by rectal palpation and/or ultrasonography prior to treatment. Repeated use of OVUPLANT in consecutive estrous periods during the same season does not result in loss of effectiveness.
Systemic adverse reactions have not been observed with the use of OVUPLANT at the recommended dosage in greater than 500 mares. Minor local swellings have been observed at the implantation site; however, these signs resolved uneventfully without treatment within 2-5 days. In safety and tolerance studies, mares receiving either 3, 5 or 10 implants simultaneously showed no adverse effects. In a reproductive safety study, repeated administration of either 3 or 5 implants during consecutive estrous periods caused a dose-related extension of the interestrous interval, but had no adverse effects on fertility.
Ovuplant Dosage And Administration
One (1) implant should be placed subcutaneously in the neck of an estrous mare that has been determined by rectal palpation and/or ultrasonography to have an ovarian follicle greater than 30 mm in diameter. Effectiveness is contingent upon accurate diagnosis of estrus and detection of a developing follicle greater than 30 mm in diameter. Only one (1) implant should be administered per mare during a given estrus.
Select the implant site by locating an area of the neck midway between the head and shoulder. Prepare the implantation site by thoroughly cleaning the skin with an appropriate disinfectant. Insert the entire length of the needle subcutaneously and fully depress the syringe plunger. Slowly withdraw the needle while pressing the skin at the insertion site. Examine the syringe and needle to verify the implant has not remained in the syringe or needle. It may be possible to palpate the implant in situ. This biocompatible implant is absorbed and does not require removal. Do not attempt to reuse the implanter. Dispose of implanter appropriately.
Breeding or insemination prior to ovulation has been shown to produce higher conception rates than post-ovulation breedings or inseminations. Breeding or insemination within 48 hours prior to ovulation is recommended for maximum conception rates. To time properly a breeding, a mare in estrus with an ovarian follicle greater than 30 mm should be implanted with OVUPLANT. The mare should then be bred or inseminated prior to ovulation within the next 48 hours. The mare should be monitored to insure ovulation did occur and further breedings are not required. If ovulation does not occur within the 48 hour period, continue breeding according to routine reproductive management procedures.
This drug is not to be administered to horses that are to be slaughtered for use in food. Keep out of reach of children. Not for human use. Exercise caution to avoid accidental injection. In case of human injection, consult a physician immediately. Do not use if the foil pouch is broken.
Store under refrigerated conditions between 2° and 8°C (36° and 46°F).
Five (5) implants per carton. OVUPLANT is formulated as a cylindrical implant in a preloaded syringe with an attached needle (implanter). Each implant contains 2.1 mg deslorelin (as deslorelin acetate). Each preloaded implanter is individually packaged in a foil pouch.
Trademarks used under license
Distributed in Canada by Wyeth Animal Health, Division of Wyeth Canada, Guelph, Ontario, Canada
Developed by Peptech Animal Health Pty Limited, North Ryde NSW 2113, Australia
NAC No.: 11983911
17,300 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9J 2M5
|Technical Services Canada:||800-461-0917|
|Technical Services USA:||800-366-5288|
|Every effort has been made to ensure the accuracy of the Ovuplant information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-07-10